New hope for kids whose leukemia Won't quit

NCT ID NCT06466395

Summary

This early-stage study is testing the safety and best dose of a two-drug combination (Hyper-CVAD and venetoclax) for children and young adults (ages 2-21) whose leukemia has returned or hasn't responded to other treatments. The main goal is to see how much of the drug combination can be given safely. Researchers will also look for early signs that the treatment might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNDIFFERENTIATED LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.